{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-061524","form_type":"8-K","ticker":"IKT","cik":"0001750149","company_name":"Inhibikase Therapeutics, Inc.","filed_at":"2023-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.404470+00:00","generated_at":"2026-06-18T11:53:56.035727+00:00","sec_items":["5.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Inhibikase Therapeutics awards stock options to CEO and CFO with performance vesting tied to Phase 2a study","bullets":["CEO Milton H. Werner granted options for 315,000 shares at $0.7390; 105,000 subject to performance vesting.","CFO Joseph Frattaroli granted options for 135,000 shares at $0.7390; 45,000 subject to performance vesting.","Performance milestones tied to completion and release of IKT-148009 Phase 2a study in Parkinson's disease.","Remaining options subject to time vesting under 2020 Equity Incentive Plan."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-061524","json":"https://secwatch.observer/filing/0001193125-23-061524.json","markdown":"https://secwatch.observer/filing/0001193125-23-061524.md","text":"https://secwatch.observer/filing/0001193125-23-061524.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750149/000119312523061524/0001193125-23-061524-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750149/000119312523061524/d410993d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T11:53:56.035727+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}